Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Metabolic targeting of ASAH1 in combination with carnosine as a therapeutic strategy for TNBC. Local targets link to admitted publications; unresolved targets remain external evidence.
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival
10.3121/cmr.2008.825 · 2009 · External reference
Triple-negative breast cancer molecular subtyping and treatment progress
10.1186/s13058-020-01296-5 · 2020 · External reference
Optimal systemic treatment for early triple-negative breast cancer
10.1159/000508759 · 2020 · External reference
Treatment landscape of triple-negative breast cancer - expanded options, evolving needs
10.1038/s41571-021-00565-2 · 2022 · External reference
Therapies for triple negative breast cancer
10.1517/14656566.2015.1032246 · 2015 · External reference
Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take
10.15252/embr.202050635 · 2020 · External reference
Cancer cells don't live alone: metabolic communication within tumor microenvironments
10.1016/j.devcel.2020.06.018 · 2020 · External reference
Targeting cancer metabolism in the era of precision oncology
10.1038/s41573-021-00339-6 · 2022 · External reference
The influence of metabolism on drug response in cancer
10.3389/fonc.2018.00500 · 2018 · External reference
Metabolomics analysis reveals altered metabolic pathways and response to doxorubicin in drug-resistant triple-negative breast cancer cells
10.3390/metabo13070865 · 2023 · External reference
Metabolic changes in triple negative breast cancer-focus on aerobic glycolysis
10.1007/s11033-021-06414-w · 2021 · External reference
Metabolic reprogramming in triple-negative breast cancer
10.20892/j.issn.2095-3941.2019.0210 · 2020 · External reference
Metabolic targets for cancer therapy
10.1038/nrd4145 · 2013 · External reference
Emerging therapies in cancer metabolism
10.1016/j.cmet.2023.07.006 · 2023 · External reference
Clinical development of metabolic inhibitors for oncology
10.1172/jci148550 · 2022 · External reference
Targeting metabolic vulnerabilities of cancer: small molecule inhibitors in clinic
2019 · External reference
ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability
10.1038/s41419-024-06831-2 · 2024 · External reference
Acid ceramidase promotes senescent cell survival
10.18632/aging.203170 · 2021 · External reference
N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production
10.1016/j.molmet.2021.101217 · 2021 · External reference
Acid ceramidase (ASAH1) is a global regulator of steroidogenic capacity and adrenocortical gene expression
10.1210/me.2011-1150 · 2012 · External reference
The anti-cancer activity of the naturally occurring dipeptide carnosine: potential for breast cancer
10.3390/cells12222592 · 2023 · External reference
Carnosine suppresses human glioma cells under normoxic and hypoxic conditions partly via inhibiting glutamine metabolism
10.1038/s41401-020-0488-1 · 2021 · External reference
Carnosine suppresses human colorectal cancer cell proliferation by inducing necroptosis and autophagy and reducing angiogenesis
10.3892/ol.2021.13162 · 2022 · External reference
Profiling and targeting of cellular mitochondrial bioenergetics: inhibition of human gastric cancer cell growth by carnosine
10.1038/s41401-018-0182-8 · 2019 · External reference
Inhibition of tumour cell growth by carnosine: some possible mechanisms
10.1007/s00726-013-1627-5 · 2014 · External reference
Anti-cancer effects of Carnosine-A dipeptide molecule
10.3390/molecules26061644 · 2021 · External reference
Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine
10.1038/bjc.1996.189 · 1996 · External reference
Hmdb 5.0: the human metabolome database for 2022
10.1093/nar/gkab1062 · 2022 · External reference
Carnosine inhibits the proliferation of human gastric cancer SGC-7901 cells through both of the mitochondrial respiration and glycolysis pathways
10.1371/journal.pone.0104632 · 2014 · External reference
Carnosine inhibits KRAS-Mediated HCT116 proliferation by affecting ATP and ROS production
10.1016/j.canlet.2011.07.021 · 2012 · External reference
Discovery and evaluation of inhibitors of human ceramidase
10.1158/1535-7163.mct-11-0365 · 2011 · External reference
Targeting ceramide metabolic pathway induces apoptosis in human breast cancer cell lines
10.1016/j.bbrc.2015.07.047 · 2015 · External reference
The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro
10.1007/s10616-017-0154-8 · 2018 · External reference
Examining impacts of ceranib-2 on the proliferation, morphology and ultrastructure of human breast cancer cells
10.1007/s10616-016-9997-7 · 2016 · External reference
Current methods for quantifying drug synergism
2019 · External reference
Carnosine mitigates manganese mitotoxicity in an in vitro model of isolated brain mitochondria
10.15171/apb.2019.034 · 2019 · External reference
Carnosine inhibits the proliferation of human cervical gland carcinoma cells through inhibiting both mitochondrial bioenergetics and glycolysis pathways and retarding cell cycle progression
10.1177/1534735416684551 · 2018 · External reference
Therapeutic efficacy of natural dipeptide carnosine against human cervical carcinoma cells
10.1002/jmr.2541 · 2016 · External reference
Improved apoptosis and mitochondrial dysfunction: the potential of carmofur-platinum nanoparticles
10.1088/1748-605x/adcbfa · 2025 · External reference
Mitochondria in health, disease, and aging
10.1152/physrev.00058.2021 · 2023 · External reference
Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement
10.1016/j.redox.2020.101674 · 2020 · External reference
Fifty years of research on protonophores: mitochondrial uncoupling as a basis for therapeutic action
10.32607/actanaturae.11610 · 2022 · External reference
Mitochondrial regulation of calcium in the Avian cochlear nucleus
10.1152/jn.1997.78.4.1928 · 1997 · External reference
Metabolic reprogramming and cancer progression
10.1126/science.aaw5473 · 2020 · External reference
Metabolic reprogramming: a friend or foe to cancer therapy?
10.3390/cancers13133351 · 2021 · External reference
Metabolic reprogramming in triple-negative breast cancer
10.3389/fonc.2020.00428 · 2020 · External reference
Physiology and pathophysiology of carnosine
10.1152/physrev.00039.2012 · 2013 · External reference
Taurine uptake across the human intestinal brush-border membrane is via two transporters: H+-Coupled PAT1 (SLC36A1) and Na+- and Cl(-)-dependent TauT (SLC6A6)
10.1113/jphysiol.2008.164228 · 2009 · External reference
Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1)
10.1002/jcp.20337 · 2005 · External reference
The human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health
10.3389/fchem.2018.00243 · 2018 · External reference
Carnosine, small but mighty-prospect of use as functional ingredient for functional food formulation
10.3390/antiox10071037 · 2021 · External reference
Stressed to death: mitochondrial stress responses connect respiration and apoptosis in cancer
10.1016/j.molcel.2022.07.012 · 2022 · External reference
Mitochondrial apoptosis: killing cancer using the enemy within
10.1038/bjc.2015.85 · 2015 · External reference
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity
10.1038/srep01035 · 2013 · External reference
Molecular mechanism of inhibition of acid ceramidase by carmofur
10.1021/acs.jmedchem.8b01723 · 2019 · External reference
Combination strategies to target metabolic flexibility in cancer
10.1016/bs.ircmb.2022.03.001 · 2022 · External reference
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes
10.1038/s41418-025-01532-5 · 2025 · External reference
Dietary carnosine supplementation in healthy human volunteers: a safety, tolerability, plasma and brain concentration study
10.3390/nu17132130 · 2025 · External reference
Evaluation of supplementary carnosine accumulation and distribution: an initial analysis of participants in the nucleophilic defense against PM toxicity (NEAT) clinical trial
10.1007/s00726-024-03414-5 · 2024 · External reference
